Introduction Cancer pain management is one of the most critical issues of modern oncology, while its pathophysiology remains poorly researched. The use of opioids is the key strategy used to alleviate chronic pain and increase patients’ quality of life. The recent study shows that there is a connection between a neural system, cancer cells, and host’s immune, which allows assuming the potential beneficial role of Cannabidiol (CBD) that impacts on a person’s endocannabinoid system (ECS) (Chwistek, 2017). In this connection, this paper aims to propose the investigation of the role of CBD in cancer pain management as a therapeutic means with less unwanted side effects compared to opioids. PICOT Question and Available Literature The following PICOT question is proposed to be explored: in cancer patients (P), how does Cannabidiol (CBD) (I) compared with opioids (C) affect pain over chemotherapy treatment (O) in 2 months (T)? The patients having chemotherapy are selected for the proposed study as the category of people who often encounter peripheral neuropathic pain due to their treatment (Wiffen, Wee, Derry, Bell, & Moore, 2017). It makes them socially inactive and poses the threat of mental complications. These patients receive opioids, such as tramadol, morphine, methadone, and others, the effectiveness and safety of which are under the question. Page and Blanchard (2019) report that the opioid epidemic is escalating: “43% of patients with cancer and 10% of survivors use opioids to manage chronic cancer pain”, of which 47, 000 die due to overdose annually (p. 229). Since the majority of cancer patients and survivors experience chronic pain, there is a need to find a more relevant way to assist them in managing their health and maintain their life quality. Today, cancer is treated with chemotherapy therapy, which can cause inflammation and destruction of healthy tissues, which is complicated with the main problems associated with this disease, including pain, loss of appetite, and nausea. CBD that is selected as the intervention for the proposed study interacts with the cannabinoid cell receptors on its surface to activate and enhance the response of the nervous system (Degenhardt et al., 2015). Two cannabinoid receptors are present in the human body, such as CB1 and CB2. CBD has the effect that is similar to the one that one’s body reproduces in a natural way. There are scientific works that testify in favor of the fact that CBD has anti-inflammatory and analgesic features. In this regard, it is possible to suggest that this substance will help in the development of effective drugs against moderate and sever pain caused by cancer and chemotherapy. A 2-months period is selected for the study to reveal any impact of CBD on cancer patients since this timeframe will allow understanding the rapid pain relief. It is suggested that the mentioned period is sufficient to identify the positive and negative effects of the discussed intervention. Among the expected outcomes, there is a substantial or complete pain relief for patients who pass chemotherapy and need to increase their comfort levels. Considering that the implementation of new projects in healthcare environment requires high costs, 60 days seem to be the most pertinent timeline to understand the impact of CBD on patie